Background and purpose: No prospective study has evaluated the impact of restless legs syndrome (RLS) on clinical factors in patients with migraine. We planned a prospective study to assess the impact of RLS comorbid status on clinical factors in patients with migraine. Methods: A total of 101 patients with migraine who were evaluated for RLS twice at 7-year intervals in a university hospital setting were included in this study. The RLS group was defined as positive for RLS at either baseline or follow-up and the non-RLS group was defined as negative for RLS at both baseline and follow-up. The Migraine Disability Assessment (MIDAS) questionnaire, Beck Depression Inventory-II (BDI-II), Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale were administered to all patients. Results: The RLS prevalence was 16.8% at baseline and 20.8% at follow-up. Compared with the non-RLS group (n = 27), the RLS group (n = 74) showed a significantly higher rate of smoking and higher MIDAS and BDI-II scores at 7-year follow-up. A significant reduction in MIDAS and BDI-II scores at 7-year follow-up compared with those at baseline was observed in the non-RLS group, but not in the RLS group. The non-RLS group showed a significantly lower MIDAS score at 7-year follow-up than the RLS group after adjusting for confounding variables such as age, gender, smoking status, Epworth Sleepiness Scale and PSQI scores using analysis of covariance. The persistent RLS group (n = 11) (positive for RLS at both baseline and followup) showed a significantly higher rate of smoking and increased MIDAS, BDI-II and PSQI scores compared with the non-RLS group (n = 74) at 7-year follow-up. Conclusion: Our prospective study showed that RLS had a significant impact on headache-related disability in patients with migraine.
Introduction
Migraine is a disabling neurological disorder that affects 18% of women and 6% of men annually [1] . Recently, migraine has been reported to be the leading cause of years lived with disability for patients between the ages of 15 and 49 years [2] . This finding highlights the negative influences on daily functioning and quality of life of migraine sufferers. Therefore, it is imperative to identify the factors that exacerbate headaches and affect patients' daily functioning. Headache chronicity [3] , severity of accompanying symptoms (photophobia, phonophobia, nausea) [4] and comorbid conditions such as asthma, chronic musculoskeletal pain [5] and depression [6] have been associated with the impaired quality of life of patients with migraine.
Restless legs syndrome (RLS) is a sensorimotor disorder that causes insomnia due to abnormal sensations in the legs. The prevalence of RLS in patients with migraine (8.7-39 .0%) has been reported to be higher than that of healthy control subjects [7] . A significant association between RLS and migraine has been replicated in multiple case-controlled [8] [9] [10] and populationbased studies [11] [12] [13] , and migraine is now considered to be a significant comorbid condition of RLS [14] . Cross-sectional studies have shown an increased prevalence of RLS in patients with migraine and relationships between RLS and headache-related disabilities and sleep disturbances [15, 16] . However, there has been no prospective study evaluating the impact of RLS on clinical factors in patients with migraine and the clinical implications of comorbid RLS for patients with migraine have yet to be determined.
Considering the impact of RLS on sleep disturbances and mood disturbances, we hypothesized that patients with migraine who have never experienced RLS symptoms would have fewer headache-related disabilities than patients with migraine who have experienced RLS symptoms. To prove our hypothesis, we planned a prospective study to assess the impact of RLS comorbid status on clinical factors in patients with migraine over a 7-year interval.
Methods
In 2010, 262 patients with migraine (age 38.2 AE 13.0 years; 47 men, 215 women) diagnosed according to the International Classification of Headache Disorders, second edition [17] were evaluated for RLS. Over a 7-year period, 161 patients were lost to followup and 101 patients (49.4 AE 11.8 years, 10 men, 91 women) were evaluated with the same assessments at baseline and at 7-year follow-up that took place between April and November 2017. This prospective study included 101 patients with migraine who were available at baseline and at 7-year follow-up (Fig. 1) .
Clinical assessments
All patients with migraine completed questionnaires that assessed habits (sleep, smoking and alcohol and caffeine intake), sleep disturbances, depressive state and RLS twice, with a 7-year interval between assessments. At baseline and follow-up, RLS was diagnosed according to the criteria developed by the International RLS Study Group [18] . Four essential features should be present for diagnosis: (i) an urge to move the legs, usually accompanied or caused by uncomfortable and unpleasant sensations in the legs; (ii) the urge to move the legs and any accompanying unpleasant sensations begin or worsen during periods of rest or inactivity, such as lying down or sitting; (iii) the urge to move the legs and any accompanying unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues; and (iv) the urge to move the legs and any accompanying unpleasant sensations during rest or inactivity only occur or are worse in the evening or night than during the day. RLS diagnosis was confirmed by neurologists after excluding secondary RLS or RLS mimics such as positional discomfort, muscle cramps, venous stasis, vascular or neurogenic claudication and peripheral neuropathy. In this study, the RLS group was defined as patients who were positive for RLS at either baseline or follow-up and the non-RLS group was defined as patients who were negative for RLS at both baseline and follow-up ( Fig. 1) . Clinical characteristics at baseline and follow-up were compared between the RLS and non-RLS groups, and changes in clinical parameters were compared between baseline and follow-up within the RLS and non-RLS groups. Additionally, a persistent RLS group, defined as patients who were positive for RLS at both baseline and followup, was compared with the non-RLS group. In the persistent RLS group, changes in RLS severity were assessed by the International RLS Study Group rating scale [19] .
Headache-related disabilities over the previous 3 months were evaluated with the Migraine Disability Assessment (MIDAS) questionnaire [scores ranging from 0 (no disability) to 270 (worst disability)] [20] . The information about headache frequency (times/ month) and headache intensity (0-10) was obtained from the MIDAS A and B. The Beck Depression Inventory-II (BDI-II) was used to evaluate depressive symptoms [21] . The Pittsburgh Sleep Quality Index (PSQI) was used and insomnia was diagnosed with a PSQI global score of ≥6 [22] . PSQI component scores were also evaluated (C1, sleep quality; C2, sleep latency; C3, sleep duration; C4, habitual sleep efficiency; C5, sleep disturbances; C6, use of sleeping medications; C7, daytime dysfunctions). Daytime sleepiness was evaluated using the Epworth Sleepiness Scale (ESS) [23] . An ESS score of ≥10 was defined as excessive daytime sleepiness.
This study was approved by the Institutional Review Board of Dokkyo Medical University and written informed consent was obtained from all patients included in the study.
Statistical analysis
Mann-Whitney U-tests or Student's t-tests were used where appropriate to compare continuous variables and chi-square or Fisher's exact tests were used to compare categorical variables between patients with migraine with and without RLS at both baseline and follow-up assessments. The MIDAS, BDI-II, PSQI and ESS scores had non-normal distributions, so logarithmic transformations were performed by replacing 0 scores with 1 scores. Paired t-tests were used to compare MIDAS, BDI-II, PSQI and ESS scores between baseline and follow-up from patients with or without RLS after log-transformations. Based on these results, after log-transformations, we compared differences in MIDAS and BDI-II scores between patients with migraine with and without RLS at 7-year follow-up using Bonferroni tests and ANCOVA, adjusting for confounding factors (input criteria were variables with P < 0.1 in Table 1 , excluding age and gender): model 1, MIDAS or BDI-II baseline; model 2, model 1 plus age and gender; model 3, model 2 plus current smoking status and log-transformed PSQI and ESS scores; and model 4, model 3 plus headache frequency and severity [24, 25] . Two-tailed P < 0.05 was considered to be statistically significant. IBM SPSS Statistics software version 24.0 (IBM SPSS, Inc., Tokyo, Japan) was used for statistical analyses.
Results Figure 1 illustrates RLS status at baseline and followup in our cohort of patients with migraine.
Patients were classified into two groups, i.e. an RLS group (n = 27) and a non-RLS group (n = 74). The RLS prevalence was 16.8% at baseline and 20.8% at follow-up assessments. Table 1 shows the characteristics of patients with migraine classified by RLS status at baseline and at 7-year follow-up. At baseline, the RLS group had a significantly higher rate of smoking and higher PSQI and ESS scores than the non-RLS group. At the 7-year follow-up assessment, the RLS group showed a significantly higher rate of smoking and higher MIDAS and BDI-II scores than the non-RLS group. No significant difference was found in headache frequency (times/ month) or severity between the RLS and non-RLS groups at baseline and 7-year follow-up. At both baseline and follow-up, the use of migraine treatments, including antiepileptic drugs, antidepressants, triptans and NSAIDs, was similar between the RLS and non-RLS groups (Table 1) . To address the bias associated with patients who completed the study (n = 101), the baseline characteristics were compared with those of patients who were lost to follow-up (n = 161) (Table S1 ). Patients who were lost to follow-up were significantly younger and had fewer chronic migraines and lower MIDAS scores than those who completed the study. The use of tricyclics, selective serotonin reuptake inhibitors or serotoninnorepinephrine reuptake inhibitors did not differ between the RLS and non-RLS groups. We then compared the clinical characteristics of the persistent RLS group (n = 11), which included patients who were positive for RLS at both baseline and follow-up, with those of the non-RLS group (n = 74). The persistent RLS group showed a significantly higher rate of smoking (45.5% vs. The MIDAS and BDI-II scores were significantly lower at 7-year follow-up than at baseline in the non-RLS group, but there were no differences in these scores between baseline and 7-year follow-up in the RLS group (Table 2) . Table 3 shows differences in MIDAS and BDI-II scores between the RLS and non-RLS groups at 7-year follow-up based on ANCOVA after adjustments for confounding factors in the different models. The MIDAS score remained significantly lower in the non-RLS group than in the RLS group, even in the final model, which adjusted for the baseline MIDAS or BDI-II score, age, gender, smoking status, PSQI and ESS scores, and headache frequency and severity. However, the BDI-II score was not significantly different based on RLS comorbidity in any model. Mann-Whitney test. 
RESTLESS LEGS SYNDROME PREDICTS DISABILITY IN MIGRAINE

Discussion
In this prospective study, we evaluated 101 patients with migraine for RLS and other clinical parameters twice, with a 7-year interval between assessments, to investigate the impact of RLS comorbidity on clinical symptoms of migraine. RLS prevalence rates were similar at baseline (16.8%) and at 7-year follow-up (20.8%). Although the increased prevalence of RLS in patients with migraine compared with healthy subjects has been confirmed in several case-controlled studies [7] , prospective evaluations of RLS status in patients with migraine have not been previously performed. We showed that, in patients with migraine who were not diagnosed with RLS, MIDAS and BDI-II scores decreased significantly at 7-year follow-up, whereas in patients with migraine who were diagnosed with RLS at either baseline or follow-up, these scores did not change at 7-year follow-up. These findings indicate that RLS status may longitudinally affect mood or daytime functioning in patients with migraine.
The most important finding in our study is that RLS status was an important predictor for post-7-year headache-related disabilities in patients with migraine. Patients with migraine who were not diagnosed with RLS showed lower MIDAS scores than patients with migraine who were diagnosed with RLS at either baseline and 7-year follow-up after adjusting for confounding factors such as age, gender, insomnia, daytime sleepiness and headache frequency and intensity. Headache intensity and frequency were important factors for headache-related disability in patients with migraine [24] and RLS was more prevalent in patients with migraine who had a high headache frequency than in those with a low headache frequency [25] . However, we showed that RLS is a significant predictor of headache-related disabilities after controlling for headache frequency and severity. The persistent RLS group (patients positive for RLS at both baseline and 7-year follow-up assessment) had significantly higher MIDAS, BDI-II and PSQI scores at 7-year follow-up than the non-RLS group, highlighting the clinical significance of RLS comorbidity in patients with migraine. These findings are in line with cross-sectional observations showing associations between RLS and poor sleep and mood disturbances in patients with migraine [8, 9, 26] . RLS severity did not increase over time in the persistent RLS group in our study, but it is possible that impaired sleep status due to RLS resulted in increased headache-related disabilities. In contrast, the RLS group showed worse headache-related disabilities than the non-RLS group, after adjusting for confounding factors including sleep status. These results indicate that the comorbid RLS status itself directly impacted headache-related disabilities in patients with migraine.
In the pathophysiology of RLS, impairments have been implicated in brain iron metabolism, dopaminergic systems and opioid systems, as well as glutamate, hypocretin and adenosine systems [27] . Impairments in iron and dopamine metabolisms have been indicated to play a role in the relationship between migraine and RLS [7] . Interestingly, in a diary study of 30 patients with migraine with RLS, migraine attacks were associated with subsequent RLS attacks on the following night and RLS attacks were associated with subsequent migraine attacks on the following day. These data showed a bidirectional triggering association between migraine and RLS attacks [28] . The authors postulated that increased extracellular serotonin levels after migraine attacks may participate in an imbalance in dopamine levels, thus resulting in subsequent RLS attacks. Opposing interactions between the dorsal raphe serotonin system and the ventral tegmental and substantia nigral dopamine systems further complicate the mechanisms of coexisting migraine and RLS [29] . Taken together, imbalances in multiple neurotransmitter systems or a dysregulation of brain iron activity may be intricately implicated in the RLS-migraine relationship, based on the following observations. Dopamine antagonists relieve premonitory symptoms of migraine [30] , whereas dopamine agonists are markedly effective in ameliorating RLS symptoms [18] . In contrast, our preliminary study showed that dopamine agonists may improve migraine headaches and RLS symptoms in patients with migraine with comorbid RLS [16] . Migraine headaches worsen with movement during attacks, whereas RLS symptoms improve with movement. Increased iron depositions in multiple deep brain nuclei are related to repeated migraine attacks [31] , whereas brain iron insufficiency plays a central role in the pathogenesis of RLS [32] .
Valente et al. [9] reported that serotoninergic overload, defined as the combined use of selective serotonin reuptake inhibitors, serotonin antagonist and reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors and the presence of triptan abuse, was related to RLS occurrence in patients with migraine. The authors suggest that serotoninergic imbalances may play a role in RLS comorbidity in patients with migraine. However, in our study, no differences were found in the use of acute or prophylactic treatments between patients with migraine with and without RLS. In a study using functional magnetic resonance imaging, disrupted functional connectivity in the default mode and in the cingulo-opercular and sensory/somatomotor networks in patients with migraine with RLS and a negative correlation between RLS severity and connections between the default mode and subcortical networks were observed [33] . A high prevalence of dopaminergic premonitory symptoms, such as yawning, nausea, somnolence or food cravings, have also been reported in patients with migraine with RLS [34] .
Another possible shared mechanism for RLS and migraine is brain hypersensitivity. Hypersensitivity to pain [35] and sensory stimuli [36] and central sensitization [37, 38] have been shown to be involved in the pathophysiology of migraine and RLS, respectively. The hypersensitivity of corticostriatal glutamatergic terminals in a brain iron-deficiency model of RLS has recently been shown [39] . Finally, considering familial predispositions for migraine and RLS, genetic or environmental factors may also play a role. A study investigating 13 single-nucleotide polymorphisms at six RLS risk loci showed that MEIS1 variants were associated with an increased risk of RLS in patients with migraine [40] .
One limitation of our study is that, during the 7-year period, 161 patients were lost to follow-up and unable to participate in the follow-up assessment. Patients who were lost to follow-up had fewer chronic migraines and lower MIDAS scores than those who completed the follow-up, which may have impacted the study results. However, in clinical practice, patients with relatively benign courses are likely to be lost to follow-up and this selection bias is not considered large, given that the prevalence of RLS between the groups was not significantly different (11.6% vs. 16.8%). In addition, during the follow-up period, data regarding treatments for RLS and temporal associations between RLS symptoms and migraine attacks were not available in this study. Further prospective studies are warranted to confirm the RLS-migraine relationship and to assess if RLS treatment could improve the daytime functioning and quality of life of migraine sufferers.
In conclusion, our prospective study confirmed a significant relationship between migraine and RLS. RLS comorbidity was a significant predictor for headache-related disabilities in patients with migraine. Table S1 . Baseline characteristics of patients with migraine who were lost to follow-up and those who completed follow-up.
